Ken Griffin Akero Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$21.45 - $29.34 $356,070 - $487,044	-16,600 Reduced 28.72%	41,200 $1.18 Million
Q2 2024 Aug 14, 2024	SELL	$18.31 - $24.62 $355,214 - $477,628	-19,400 Reduced 25.13%	57,800 $1.36 Million
Q1 2024 May 15, 2024	SELL	$17.76 - $31.18 $383,616 - $673,488	-21,600 Reduced 21.86%	77,200 $1.95 Million
Q4 2023 Feb 14, 2024	BUY	$11.38 - $50.33 $718,078 - $3.18 Million	63,100 Added 176.75%	98,800 $2.31 Million
Q3 2023 Nov 14, 2023	BUY	$41.19 - $52.25 $416,019 - $527,725	10,100 Added 39.45%	35,700 $1.81 Million
Q2 2023 Aug 14, 2023	SELL	$36.89 - $56.88 $1.01 Million - $1.55 Million	-27,300 Reduced 51.61%	25,600 $1.2 Million
Q1 2023 May 15, 2023	SELL	$37.27 - $50.24 $2.63 Million - $3.54 Million	-70,500 Reduced 57.13%	52,900 $2.02 Million
Q4 2022 Feb 14, 2023	BUY	$33.44 - $54.8 $1.73 Million - $2.83 Million	51,700 Added 72.11%	123,400 $6.76 Million
Q3 2022 Nov 14, 2022	BUY	$10.15 - $34.05 $727,755 - $2.44 Million	71,700 New	71,700 $2.44 Million

190

73.8M

241K

647K

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $1.29B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.